Osteoporosis has been defined as a systemic skeletal disease that is characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture [1]. The basic pathogenesis of osteoporosis is deregulation of bone formation and resorption. Ovariectomized mice are an accepted in vivo model of human Postmenopausal osteoporosis (PMOP). Bone mineral density (BMD) measurement, micro-CT analysis and histomorphometric analysis were used to evaluate the OVX mice [2, 3]. Bones were harvested and tested after the operation.
A stable OVX-induced osteoporosis disease model protocol was established in C57BL/6 mice by Biocytogen, which can be used for preclinical studies and pharmacodynamic evaluation of osteoporosis.